Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

NCT01260688 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

NIH

Sponsor class

Conditions

Hormone Refractory Prostate Cancer
Recurrent Prostate Cancer

Interventions

DRUG: cediranib maleate
DRUG: dasatinib

Sponsor

National Cancer Institute (NCI)